Avacta announces EU registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test
Avacta Group, the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, has received notice of registration of its AffiDX® SARS-CoV-2 antigen lateral flow test in the EU allowing the company to market the product in the EU for professional use. Lateral flow antigen tests are intended to provide […]
